Posted on September 10, 20259/10/25
The Evolution of the 340B Rebate Model: Maintaining Patient Access while Minimizing Duplicate Discounts
Posted on September 10, 20259/10/25
2026 CMS Proposed Rule: BFSF Changes and Potential Risks for Pharma Manufacturers
Posted on September 10, 20259/10/25
Navigating OBBBA: Why a Strong GP Team is Essential for Pharma Compliance
Posted on August 22, 20258/22/25
Navigating MFN: Alan Crowther on What Pharma Brands Must Know Now
Posted on July 22, 20257/22/25
Case Study: Transforming Market Access with NAVLIN Insights KPI
Posted on July 8, 20257/8/25
Navigating the Not-So-Direct Path to Access – A Pharmacist’s Perspective
Posted on May 23, 20255/23/25
Most Favored Nation Pricing | Insights and Implications for Manufacturers
Posted on April 11, 20254/11/25
Unlocking Pharma Success: Mike Ryan’s Pre-Conference Talk at Reuters Pharma 2025
Posted on September 30, 20249/30/24
Unlocking the Power of Tender Data to Drive Post-LOE Pricing Strategy
Posted on September 13, 20249/13/24